MedTrace Logo

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

NCT04865419 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.

Conditions

  • Haematological Malignancies

Interventions

DRUG

AZD0466

AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.

DRUG

Voriconazole

Voriconazole film-coated tablet will be administered orally.

Sponsors & Collaborators

Principal Investigators

  • Nitin Jain, MD, PhD · The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard, Unit 431 Houston, Texas 77030 United States of America

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2023-08-08
Completion
2023-08-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Germany
  • Italy
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04865419 on ClinicalTrials.gov